| Literature DB >> 25332694 |
Jonnie N Asegbeloyin1, Oguejiofo T Ujam1, Emmanuel C Okafor1, Ilknur Babahan2, Esin Poyrazoglu Coban3, Ali Ozmen3, Halil Biyik3.
Abstract
Reaction of 1-phenyl-3-methyl-4-benzoyl-pyrazol-5-one and benzoyl hydrazide in refluxing ethanol gave N (')-[(Z)-(3-methyl-5-oxo-1-phenyl-1,5-dihydro-4H-pyrazol-4-ylidene)(phenyl)methyl]benzohydrazide (HL(1)), which was characterized by NMR spectroscopy and single-crystal X-ray structure study. X-ray diffraction analyses of the crystals revealed a nonplanar molecule, existing in the keto-amine form, with intermolecular hydrogen bonding forming a seven-membered ring system. The reaction of HL(1) with Co(II), Ni(II), and Cu(II) halides gave the corresponding complexes, which were characterized by elemental analysis, molar conductance, magnetic measurements, and infrared and electronic spectral studies. The compounds were screened for their in vitro cytotoxic activity against HL-60 human promyelocytic leukemia cells and antimicrobial activity against some bacteria and yeasts. Results showed that the compounds are potent against HL-60 cells with the IC50 value ≤5 μM, while some of the compounds were active against few studied Gram-positive bacteria.Entities:
Year: 2014 PMID: 25332694 PMCID: PMC4181943 DOI: 10.1155/2014/718175
Source DB: PubMed Journal: Bioinorg Chem Appl Impact factor: 7.778
Figure 1Synthesis of HL1.
Crystal data and structure refinement details for HL1.
| Identification code | HL1 |
|---|---|
| Formula | C24H20N4O2 |
| Formula weight | 396.44 |
| Temperature (K) | 109(2) |
| Wavelength (Å) | 0.71073 |
| Crystal system | Triclinic |
| Space group | P-1 |
|
| 9.0895(2) |
|
| 10.9699(3) |
|
| 11.0637(3) |
| α/° | 89.5410(10) |
|
| 78.6940(10) |
|
| 66.0660(10) |
| Volume (Å3) | 985.59(4) |
|
| 2 |
| Calculated density (Mg/m3) | 1.336 |
| Absorption coefficient (mm−1) | 0.088 |
|
| 416 |
| Crystal size (mm3) | 0.70 × 0.49 × 0.28 mm |
| Theta range for data collection | 2.50 to 34.28° |
| Limiting indices | −14 ≤ |
| Reflections collected/unique | 29726/7289 [ |
| Completeness to theta | 27.50° 100.0% |
| Absorption correction | Multiscan |
| Max. and min. transmission | 0.9759 and 0.9412 |
| Refinement method | Full-matrix least-squares on |
| Data/restraints/parameters | 7289/0/278 |
| Goodness of fit on | 1.028 |
| Final |
|
|
|
|
| Largest diff. peak and hole | 0.440 and −0.289 e A−3 |
Figure 2Molecular structure of HL1 showing the atom numbering scheme with thermal ellipsoids at the 50% probability level.
Selected bond lengths (Å) and bond angles (°) for HL1 (estimated standard deviations are in brackets).
| Bond lengths and atomic distances (Å) | |||
| O(1)-C(8) | 1.2396(9) | N(3)-C(16) | 1.3097(11) |
| O(2)-C(18) | 1.2655(9) | N(3)-N(4) | 1.4003(10) |
| N(1)-C(7) | 1.3299(10) | N(4)-C(18) | 1.3766(10) |
| N(1)-N(2) | 1.3820(9) | N(4)-C(19) | 1.4140(10) |
| N(2)-C(8) | 1.3487(10) | C(1)-C(2) | 1.3899(13) |
|
| |||
| Bond angles (°) | |||
| C(7)-N(1)-N(2) | 123.33(7) | N(1)-C(7)-C(17) | 125.71(7) |
| C(8)-N(2)-N(1) | 119.20(7) | N(1)-C(7)-C(6) | 112.99(7) |
| C(16)-N(3)-N(4) | 106.36(6) | O(1)-C(8)-N(2) | 122.97(7) |
| C(18)-N(4)-N(3) | 112.14(6) | O(1)-C(8)-C(14) | 122.98(7) |
| C(18)-N(4)-C(19) | 129.16(7) | N(2)-C(8)-C(14) | 114.05(7) |
| N(3)-N(4)-C(19) | 118.67(6) | O(2)-C(18)-N(4) | 124.30(7) |
Figure 3A view of the crystal packing of HL1 showing the intramolecular and intermolecular hydrogen bonding.
Elemental analysis and physical data of the ligand and complexes.
| Compound | Colour | MF | Yield % | Elemental analysis % found (calculated) |
|
| Melting Point °C | |||
|---|---|---|---|---|---|---|---|---|---|---|
| C | H | N | M | |||||||
| HL1 | Yellow | C24H20N4O2 | 85 | 72.68 | 5.21 | 14.28 | — | — | — | 196 |
| CoL1
2
| Yellow | C48H40N8O5Co | 70 | 66.34 | 4.98 | 12.99 | 6.35 | 4.93 | 11.56 | 286 |
| NiL1
2
| Green | C48H40N8O5Ni | 67 | 66.78 | 4.81 | 13.02 | 6.60 | 2.94 | 12.50 | 272 |
| CuL1
2
| Green | C46H40N8O5Cu | 60 | 65.61 | 5.15 | 13.41 | 7.63 | 1.90 | 10.34 | 260 |
Relevant IR absorption bands for the ligand and metal complexes.
| Compound |
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|
| L1 | — | 3132 | 1645 | 1596 | — | 1117 | — | — | — |
| Cu(L1)2
| 3448 | 3311 | 1597 | — | 1567 | 1026 | 1440 | 519 | 418 |
| Ni(L1)2
| 3376 | 3059 | 1621 | — | 1570 | 1027 | 1437 | 509 | 460 |
| Co(L1)2
| 3468 | 3275 | 1623 | — | 1566 | 1025 | 1438 | 510 | 472 |
aHydrazide moiety, bpyrazolone ring.
Electronic spectra data of ligand and metal complexes.
| Compounds | Bands (cm−1) ( | Assigned transition |
|---|---|---|
| HL1 | 42,533 (10600) |
|
| 32,786 (7500) |
| |
| 29,411 (9100) |
| |
|
| ||
| CoL1
2
| 21,276 (228) |
4T1g(F) |
| 20,408 (224) |
4T1g(F) | |
| 10,204 (165) |
4T1g(F) | |
|
| ||
| CuL1
2
| 13,424(255) |
2B1g
|
| 16,354(135) |
2B1g
| |
| 22,722 (245) |
2B1g
| |
|
| ||
| NiL1
2
| 23,809 (225) |
3A2g
|
| 14,174 (172) |
3A2g
| |
| 12,545 (142) |
3A2g
| |
Figure 4Proposed structures of the metal complexes {M=Co(II), Cu(II), Ni(II)}.
Antimicrobial activities of HL1 and the metal complexes (inhibition zone diameter (mm).
| Test microorganism | HL1 | CoL1
2
| NiL1
2
| CuL1
2
|
|---|---|---|---|---|
|
| — | — | — | — |
|
| — | — | — | — |
|
| 15 | — | — | 12 |
|
| 15 | — | — | 14 |
|
| — | — | — | — |
|
| 15 | 13 | — | 10 |
|
| 13 | 8 | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
|
| — | — | — | — |
(—): zone of inhibition not included in the diameter of the well.
*Special gift from Faculty of Medicine, Adnan Menderes University. **Food isolated.
Minimum inhibitory concentration of compounds (MIC, μg·mL−1).
| Test microorganisms | HL1 | CoL1
2
| CuL1
2
| Str |
|---|---|---|---|---|
|
| 4 | NT | 16 | 32 |
|
| 4 | NT | 4 | 32 |
|
| 4 | 4 | 64 | 64 |
|
| 8 | 128 | NT | 64 |
Note: Str: streptomycin.
(NT): Not tested.
Antiproliferative activities of investigated compounds against human cancer (HL-60) cell line.
| Compounds | HL1 | CoL1
2
| NiL1
2
| CuL1
2
|
|---|---|---|---|---|
| IC50 ( | 3.36 ± 1.12 | 2.52 ± 0.22 | 2.66 ± 0.54 | 4.20 ± 1.44 |
Figure 5Inhibitory percentage (%) of compounds at 5–40 μM on HL-60 cancer cell line.